In a particular study, a bispecific antibody [(HER2)2xCD16] was employed to redirect γδT lymphocytes and NK cells expressing CD16 to HER2, thus enhancing their cytotoxic capabilities against tumor cells that express HER2 (including primary ovarian tumors). Here, ERBB2 is linked to ovarian neoplasm.